Accord Healthcare has entered into an exclusive distribution agreement with Molteni Farmaceutici for the commercialization of Sixmo® ? (buprenorphine implant). Sixmo is an opioid agonist treatment administered through a first-of-its-kind implant placed under the skin for six months. Approved in Europe , it will provide a convenient treatment option for those who need it.